Literature DB >> 15699390

Thymus changes in anti-MuSK-positive and -negative myasthenia gravis.

L Lauriola1, F Ranelletti, N Maggiano, M Guerriero, C Punzi, F Marsili, E Bartoccioni, A Evoli.   

Abstract

Morphologic findings of thymuses from 32 anti-acetylcholine receptor (AChR)-negative myasthenia gravis patients, 12 with and 20 without antibodies against the muscle-specific kinase (MuSK), were compared with those from 30 AChR-positive subjects. In contrast with the high frequency of thymic hyperplastic changes in AChR-positive patients, in MuSK-positive subjects histologic alterations were minimal, arguing against an intrathymic disease pathogenesis. Since hyperplastic changes were seen in 35% of MuSK-negative patients, the thymus could be involved in some of these cases.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15699390     DOI: 10.1212/01.WNL.0000150587.71497.B6

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  29 in total

1.  Microarrays reveal distinct gene signatures in the thymus of seropositive and seronegative myasthenia gravis patients and the role of CC chemokine ligand 21 in thymic hyperplasia.

Authors:  Rozen Le Panse; Géraldine Cizeron-Clairac; Jacky Bismuth; Sonia Berrih-Aknin
Journal:  J Immunol       Date:  2006-12-01       Impact factor: 5.422

2.  Myasthenia gravis thymus: complement vulnerability of epithelial and myoid cells, complement attack on them, and correlations with autoantibody status.

Authors:  Maria I Leite; Margaret Jones; Philipp Ströbel; Alexander Marx; Ralf Gold; Erik Niks; Jan J G M Verschuuren; Sonia Berrih-Aknin; Francesco Scaravilli; Aurea Canelhas; B Paul Morgan; Angela Vincent; Nick Willcox
Journal:  Am J Pathol       Date:  2007-08-03       Impact factor: 4.307

Review 3.  Muscle-Specific Tyrosine Kinase and Myasthenia Gravis Owing to Other Antibodies.

Authors:  Michael H Rivner; Mamatha Pasnoor; Mazen M Dimachkie; Richard J Barohn; Lin Mei
Journal:  Neurol Clin       Date:  2018-05       Impact factor: 3.806

Review 4.  Myasthenia gravis: an update for the clinician.

Authors:  J P Sieb
Journal:  Clin Exp Immunol       Date:  2014-03       Impact factor: 4.330

5.  Endoscopic thymectomy: a neurologist's perspective.

Authors:  Roberta Ricciardi; Franca Melfi; Michelangelo Maestri; Anna De Rosa; Afroditi Petsa; Marco Lucchi; Alfredo Mussi
Journal:  Ann Cardiothorac Surg       Date:  2016-01

6.  The high frequency and clinical feature of seronegative myasthenia gravis in Southern China.

Authors:  Hui-Yu Feng; Hai-Yan Wang; Wei-Bin Liu; Xue-Tao He; Xin Huang; Chuan-Ming Luo; Yan Li
Journal:  Neurol Sci       Date:  2012-07-25       Impact factor: 3.307

7.  Animal models of antimuscle-specific kinase myasthenia.

Authors:  David P Richman; Kayoko Nishi; Michael J Ferns; Joachim Schnier; Peter Pytel; Ricardo A Maselli; Mark A Agius
Journal:  Ann N Y Acad Sci       Date:  2012-12       Impact factor: 5.691

Review 8.  IgG4-mediated autoimmune diseases: a niche of antibody-mediated disorders.

Authors:  Maartje G Huijbers; Jaap J Plomp; Silvère M van der Maarel; Jan J Verschuuren
Journal:  Ann N Y Acad Sci       Date:  2018-01-28       Impact factor: 5.691

9.  Autoantibodies in neuromuscular transmission disorders.

Authors:  Angela Vincent
Journal:  Ann Indian Acad Neurol       Date:  2008-07       Impact factor: 1.383

10.  Muscle-specific receptor tyrosine kinase antibody positive myasthenia gravis current status.

Authors:  Shin Joong Oh
Journal:  J Clin Neurol       Date:  2009-06-30       Impact factor: 3.077

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.